• Zelgen

  Participated · Series B · Jan 2018

  Zejing Biopharma develops both chemical and biological new drugs with a focus on oncology; its lead candidate is donafenib, a multikinase inhibitor undergoing late-stage studies. The company has advanced donafenib into multiple indications, including first-line advanced hepatocellular carcinoma and trials in colorectal, thyroid, nasopharyngeal and gastric cancers. It operates an expanding pipeline with more than a dozen clinical programs across chemical and biologic assets. The company has completed GMP facilities for solid formulations and recombinant protein products and obtained an oral solid formulation production license in 2017. Management planned to secure a recombinant protein production license in the first half of 2018 to support commercial manufacturing. The recent financing supports late-stage clinical development, pre-commercial production preparation and general operations.

• Oriental Qiyin

  Led · Series B · Dec 2017

  Oriental Qiyin provides clinical speech development screening, early intervention, clinical training, and autism intervention services for children. Founded in 2007, the company has grown into the country's largest specialist chain in its sector, operating 45 direct-run centers across more than 19 cities including Beijing, Shanghai, Shenzhen and Guangzhou. It employs over 1,200 professional rehabilitation therapists and has served more than 200,000 children to date. The company emphasizes clinical practice, curriculum R&D and professional talent training, including partnerships with the University of Newcastle (Australia) and Beijing Language and Culture University to build therapist training systems. Oriental Qiyin plans to continue expanding its nationwide direct-center network, extend its course offerings across different needs, and integrate big data and AI with clinical practice to create an online-plus-offline rehabilitation service ecosystem. The firm positions itself to localize international standards for speech and autism intervention while addressing a large national talent gap through systematic training and academic cooperation. 东方启音 offers professional speech-therapy services and training programs, delivering both online and offline courses that address oral muscle and cognitive development. Its therapies are applied to children with cerebral palsy, Down syndrome, hearing impairment, ADHD, developmental delay, and autism, and the company also provides language-improvement courses for typically developing children and rehabilitation programs for adults (stuttering, post-stroke aphasia, post-surgery). The company has imported and promoted international speech-therapy techniques and works with multiple international partners to professionalize training, devices, teaching materials and software. Strategic partnerships include STAR Autism Support (collaboration on Mandarin autism training courses since 2016) and the University of Newcastle to standardize local course standards and build data-driven training plans. 东方启音 runs multiple OST-STAR centers using standardized curricula and has participated in public welfare screening and early-intervention campaigns alongside charities. Financially, the company completed a $25.0M Series B financing, which management says will support continued growth and talent development.

No current team members are available.